secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001125345-24-000161
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics Q3 net income $56.3M; cash runway into 2026; MARGENZA sale progress
-------------------------------------------------------------------------------

- Net income $56.3M ($0.90 diluted EPS) vs $17.6M in Q3 2023; revenue $110.7M driven by $100M Incyte milestone.
- Cash $200.4M at Sep 30; plus $40M MARGENZA upfront from TerSera, less $8M fee; runway into 2026.
- MARGENZA sale to TerSera for $40M upfront + up to $35M milestones; closing expected Q4 2024.
- IND for ADAM9-targeting ADC MGC028 submitted; TAMARACK mCRPC study continues, rPFS data early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000161/0001125345-24-000161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000161/mgnx-20241105.htm
  HTML page:      https://secwatch.observer/filing/0001125345-24-000161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer